Webchat: The Latest in Brain Tumor Research and Care

In honor of Brain Tumor Awareness Month, David Reardon, MD, and Patrick Wen, MD, of Dana-Farber’s Center for Neuro-Oncology, went live on Facebook to answer questions about brain cancer.

The doctors discussed advice for brain tumor patients, answered audience questions, and described the difference between the two major categories of brain cancers—primary cancer, developed in the brain, and brain metastases, which spreads from other cancers in the body.

Brain cancer has no clean margin, with cells pushing on and infiltrating normal tissues of the brain, said Wen, director of the Center for Neuro-Oncology. It is often not an easy fix to remove with just surgery, and radiation therapy can be harmful to patients’ cognitive functions.

But ongoing clinical trials at Dana-Farber are showing encouraging results for these hard-to-treat tumors, Wen said. “What’s really exciting now, in the past two to three years, is that a lot of the molecular drugs…and immunotherapies [used for cancer] elsewhere in the body are starting to be tested for brain metastases,” he added.

The two discussed precision medicines, immunotherapy, and oncolytic virotherapy – all novel treatments that are safer and have lower side effects than the current standard of care.

“It is going to take a lot more research to identify the optimal immunotherapy drugs and combinations of drugs,” explained Reardon, who serves as the Center’s clinical director. “But we are working hard at understanding that better to be able to exploit this promising new treatment approach for brain cancer patients.”

View a video of the May 23 webchat below.

Make An Appointment

For adults: 877-960-1562

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

Latest Tweets

Dana-Farber @danafarber
WATCH LIVE: Sarah Nikifrow, MD, PhD, discusses FDA approval of drug to treat adults with non-Hodgkin lymphoma: https://t.co/t1m14izqBK
Dana-Farber @danafarber
RT @KristyNBCBoston: Tonite @nbcboston news at 5, I speak w/Dr. Jacobson @DanaFarber. Car T-cell therapy gives hope to those who've run out…

Republish our posts on your blog

Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.